ABSTRACT
Purpose: To examine patterns of health care utilization and costs among cystic fibrosis (CF) patients with pulmonary infections.
Design: Retrospective administrative claims database analysis.
Methodology: We used administrative claims data (including both medical and pharmacy claims) to examine health care utilization and costs among CF patients with pulmonary infections over one year. We conducted a subgroup analysis in which we examined selected outcome measures among patients with tobramycin for inhalation (TIS) prescriptions by the number of TIS prescriptions filled.
Principal findings: Among 1,064 CF patients identified with pulmonary infections, 80% had at least one CF-related office visit, 34% had a CF-related hospital stay, and 95% filled at least one prescription over one year. Total annual CF-related health care costs averaged $29,000 plus $20,000 for prescription drugs. In the subgroup analysis, there was a trend towards longer lengths of stay and higher inpatient costs with fewer numbers of TIS prescriptions filled.
Conclusion: CF patients with pulmonary infections have substantial levels of health care utilization and costs.
More like this
- Specialty Agents With Expedited Approval May Fuel 2015 Pharmacy Costs
- Targeting a Cystic Fibrosis Mutation Opens Door for Personalized Treatment
- Early Results out From NIH-Sponsored CER Study
- FDA Panel Likes New Treatment for Idiopathic Pulmonary Fibrosis
- Don’t Forget Productivity Gains When Rating Health Programs
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.